<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699175</url>
  </required_header>
  <id_info>
    <org_study_id>HR021618-202</org_study_id>
    <nct_id>NCT04699175</nct_id>
  </id_info>
  <brief_title>A Trial of HR021618 in Postsurgical Pain Management</brief_title>
  <official_title>A Phase Ⅱ, Multicenter, Randomized, Single-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy of HR021618 for Pain Management Following Orthopaedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety of HR021618 and to explore the&#xD;
      reasonable dosage of HR021618 for Pain Management after Orthopaedic surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HR021618 compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usage of Morphine, Post Surgery</measure>
    <time_frame>0 hour to 24 hours after IP administration</time_frame>
    <description>Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 24 hour period post IP administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage of Morphine, Post Surgery at other intervals</measure>
    <time_frame>0 hour to 48 hours after IP administration</time_frame>
    <description>Change in the amount of morphine use (in milligrams) by subjects in each treatment group for 0-48 hours after IP administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity assessed using an 11-point NRS ranging</measure>
    <time_frame>Baseline till 48 hours post IP administration</time_frame>
    <description>11-point NPRS ranging from a score of 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief assessed using an 5-point likert scale</measure>
    <time_frame>Baseline till 48 hours post IP administration</time_frame>
    <description>5-point likert scale from a score of 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose of Rescue Analgesia</measure>
    <time_frame>0 hour to 48 hours after IP administration</time_frame>
    <description>Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Doses of Rescue Analgesia Utilized Per Subject</measure>
    <time_frame>0 hour to 48 hours after IP administration</time_frame>
    <description>Rescue analgesia was available to subjects with inadequately controlled pain upon request.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who received Rescue Analgesia</measure>
    <time_frame>0 hour to 48 hours after IP administration</time_frame>
    <description>Proportion of rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PGA) of Pain Control</measure>
    <time_frame>0 hour to 48 hours after IP administration</time_frame>
    <description>PGA of pain control was evaluated by subject reported degree of pain control according to a 5 point scale (0-4)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Postsurgical Pain Management</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR021618</intervention_name>
    <description>Treatment group A:HR021618; high dose</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR021618</intervention_name>
    <description>Treatment group B:HR021618; low dose</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment group C: HR021618 blank preparation.</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring elective Orthopaedic surgery&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Meet the weight standard&#xD;
&#xD;
          5. Conform to the ASA Physical Status Classification Postoperative randomization criteria&#xD;
             Exclusion Criteria&#xD;
&#xD;
        1、 Sufficient pain to require IVanalgesia assessed by NRS ranging 2、 No evidence of organ&#xD;
        insufficiency, or any other abnormality, during or following surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of major surgery&#xD;
&#xD;
          2. History of active or high-risk bleeding disorders&#xD;
&#xD;
          3. History of myocardial infarction or coronary artery bypass&#xD;
&#xD;
          4. History or clinical manifestations of significant renal, hepatic, cardiovascular,&#xD;
             metabolic, neurologic, psychiatric, or other condition that would preclude&#xD;
             participation in the study&#xD;
&#xD;
          5. Abnormal values in the laboratory&#xD;
&#xD;
          6. Have a known allergy to meloxicam or any excipient of HR021618, , aspirin, other&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative&#xD;
             medications used in this study&#xD;
&#xD;
          7. Use other drugs that affect the analgesic effect before randomization, and the time&#xD;
             from the last use to randomization is shorter than 5 half-lives&#xD;
&#xD;
          8. Planned/actual admission to the intensive care unit&#xD;
&#xD;
          9. Pregnant or nursing women&#xD;
&#xD;
         10. No birth control during the specified period of time&#xD;
&#xD;
         11. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         12. The inestigators determined that other conditions were inappropriate for participation&#xD;
             in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

